Mertens LJ
Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, lea.mertens@zi-mannheim.de.
ArticlePsilocybin
Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.
ArticlePsilocybin
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.
ArticlePsychedelics
Psychedelics: The pathway to implementation in the European healthcare systems.
ArticlePsychedelics
Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe's general change mechanisms.
ArticlePsilocybin
Compassionate use of psilocybin for treatment-resistant depression in Germany.
ArticlePsilocybin
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.
ArticleKetamine
[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].
ArticlePsilocybin
Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.
ArticlePsychedelics
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
ArticlePsilocybin
Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.
ArticlePsilocybin
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.
ArticlePsychedelics
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
ArticlePsilocybin
Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
ArticlePsychedelics
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation.
ArticlePsilocybin
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.
ArticlePsilocybin